Sarepta Therapeutics looks like breaking out Bullish
Sarepta is on the brink of a considerable breakout and the 
ARRY deal yesterday has just added more fuel to the fire. Currently sitting just below the 200ma and the $128 price level,a break above looks inevitable and all indicators are very bullish with the RSI aalso breaking out.
AVERAGE ANALYSTS PRICE TARGET $204
AVERAGE ANALYSTS RECOMMENDATION BUY
P/E RATIO
SHORT INTEREST 15%
COMPANY PROFILE
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
ARRY deal yesterday has just added more fuel to the fire. Currently sitting just below the 200ma and the $128 price level,a break above looks inevitable and all indicators are very bullish with the RSI aalso breaking out. AVERAGE ANALYSTS PRICE TARGET $204
AVERAGE ANALYSTS RECOMMENDATION BUY
P/E RATIO
SHORT INTEREST 15%
COMPANY PROFILE
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.